Alliance Pharma, the Chippenham-based speciality pharmaceutical firm, is to receive £6.7m in compensation for lost sales of a bladder cancer treatment.
ImmuCyst, one of its top-selling drugs, had peak annual sales of more than £4m before Alliance’s manufacturing partner French healthcare giant Sanofi Pasteur suspended production in mid-2012 at a Canadian plant after mold was discovered.
Alliance, which acquires and develops niche drugs, will continue to distribute ImmuCyst in the UK. It said it looked forward to bringing the product back into supply before the end of the year. 
The drug had been distributed by Alliance’s Cambridge Laboratories business since Alliance acquired the trade and certain assets of Cambridge five years ago.
The compensation, paid in cash, was in full and final settlement of Alliance’s claims, the firm said. It will be used to reduce the firm’s net bank debt.
Alliance, whose brands include the eye care product MacuShield, the Hydromol dry skin treatment, Ashton & Parsons Infants’ Powder – a natural remedy for teething pain – and Lypsyl lip balm, had made pre-tax profits of £5.5m in the six months to June 30 on revenue of £22.8m – up from £5.4m on £21.4m in the equivalent period last year.
